Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital

doi:10.19803/j.1672-8629.20230204

Abstract

Abstract: Objective To provide data for the monitoring of adverse drug reactions (ADR) induced by new anti-tumor drugs and for early warning of danger signals and pharmaceutical monitoring of ADR. Methods Ninety-one reports of ADR of new anti-tumor drugs submitted to the National Adverse Drug Reaction Monitoring Center by Jiyuan People’s Hospital between 2018 and 2022 were retrospectively analyzed according to the patients’ age, gender, BMI, primary diseases, systems-organs involved, usage of drugs and outcomes. Results ADR of new anti-tumor drugs mainly affected the skin and its accessory systems in 32 cases (35.16%), and the digestive system in 20 cases (21.98%), with diarrhea (25.00%)as the most common type of ADR in the digestive system. Multiple logistic regression analysis showed that the independent risk factors for ADR of the digestive system were lower BMI and concomitant medication. Patients with ADR of the digestive system related to immune checkpoint inhibitors took a longer time to recover (2 weeks to 1 month). Conclusion Clinical pharmacists are to be alert to ADR of new anti-tumor drugs among patients under concomitant medication or with lower BMI and manage adverse reactions caused by immune checkpoint inhibitors.

Key words: new anti-tumor drugs, adverse drug reactions, risk factors, concomitant medication, pharmaceutical care, digestive system, immune checkpoint inhibitors

CLC Number:

YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang. Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.

References

[1] HE X, WANG X, DAI HZ, et al.Analysis of the utilization of new anti-tumor drugs in the Nanjing region from 2018 to 2020[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(8): 725-730.
[2] WANG SY, WANG ZH, LI CY, et al.Progress in research on anti-tumor molecular targeted drug related diarrhea[J]. Journal of Pharmacy(药学学报), 2021, 56(12): 3377-3384.
[3] CHEN XQ, JIN YY, TANG G. New Pharmacology(新编药物学)[M]. 17th Ed, Beijing: People’s Health Publishing House, 2011: 105.
[4] National Adverse Drug Reaction Monitoring Center, National Food and Drug Administration Drug Evaluation Center. Glossary of Adverse Drug Reaction Terms (药品不良反应术语集)[M]. Beijing: China Pharmaceutical Science and Technology Press, 2003.
[5] National Health Commission. Guiding Principles for Clinical Application of Novel Antitumordrugs: 2018 Edition[EB/OL].(2018-09-21)[2023-03-10]. http://www.nhc.gov.cn/yzygj/s7659/201809/0ea15475f58a4f36b675cfa4716fa1e4.shtml.
[6] National Health Commission. Guiding Principles For Clinical Application of Novel Antitumordrugs: 2022Edition[EB/OL].(2022-12-30) [2023-03-10].http://www.nhc.gov.cn/yzygj/s7659/202212/8df034c9afb44a9d95cd986d4e12fbd8.shtml.
[7] ZHAO QL, LIN MF, CHEN J, et al.Discussion on the entry point of pharmaceutical care for lung cancer patients using new anti-tumor drugs[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(20): 2195-2197, 2202.
[8] XU WJ, GAO Y, YE ML, et al.Analysis of 346 cases of adverse reactions caused by anti-tumor drugs in a tertiary general hospital[J]. China Drug Application and Monitoring(中国药物应用与监测), 2020, 17(2): 104-107.
[9] LI YM, ZHAO ZG.Evidence based adverse reactions and pharmaceutical monitoring of ibutinib[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(7): 807-811.
[10] RUAN HB.Analysis of the use and prescription of statins for reducing blood lipid in hospitals[J]. China Practical Medicine(中国实用医药), 2017, 12(5): 147-148.
[11] HYUNA S, JACQUES F, REBECCA LS, et al.Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[12] TAI XJ, MA HF, LI J, et al.Analysis of 400 adverse reactions reports of antineoplastic drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(5): 541-544.
[13] GOMES AP, ILTER D, LOW V, et al.Age-induced accumulation of methylmalonic acid promotes tumour progression[J]. Nature, 2020(585): 283-287.
[14] ZHENG RS, ZHANG SW, ZENG HM, et al.Cancer incidence and mortality in china, 2016[J]. The Journal of the National Cancer Center, 2022, 2(1): 1-9.
[15] YANG Y, ZHOU DX, WU XL, et al.Analysis of adverse reaction reports of 84 new antitumor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(3): 334-338.
[16] CZITO BG, WILLETT CG, BENDELL JC, et al.Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase i trial results[J]. Journal of Clinical Oncology, 2006, 24: 656-662.
[17] HOPKINS AM, NQUYEN AM, KARAPETIS CS, et al.Risk factors for severe diarrhea with an afatinib treatment of non-small cell lung cancer: a pooled analysis of clinical trials[J]. Cancers (Basel), 2018, 10: 384.
[18] FAN JM, XU F.Mechanism and treatment strategies of gastrointestinal adverse reactions caused by immune checkpoint inhibitors[J]. Journal of Oncology(肿瘤学杂志), 2022, 28(2): 132-137.
[19] WU XR, YANG M.Training Materials For Reviewing Of Prescriptions By Pharmacists (药师处方审核培训教材)[M]. Beijing: China Medical Science Press, 2019.
[20] MARTHEY L, MATEUS C, MUSSINI C, et al.Cancer immunotherapy with anti-ctla-4 monoclonal antibodies induces an inflammatory bowel disease[J]. Journal of Crohn’s and Colitis, 2016, 10(4): 395-401.